VANCOUVER, British Columbia, March 16, 2021 (GLOBE NEWSWIRE)
Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce it has received product licensing paving the way for the commencement of nutraceutical marketing and sales in Q2, 2021.
Optimi Health is developing an innovative pipeline of functional, medicinal, and nutraceutical mushroom brands encompassing natural health products to proposed, future psychedelic formulations. In preparation for the public sales launch of its nutraceutical brand lineup, the Company applied for and has now received NPN licenses for six products. These include five singular mushroom strain capsules (Reishi, Chaga, Turkey Tail, Lions Mane and Cordyceps) and one proprietary Optimi formulated mixed blend capsule. To sell natural health products in Canada, companies must obtain a product license called a Natu
Optimi Health Accelerates Psilocybin Clinical Trial Program with IMPACT Commercialization of All-Natural Psychedelics Targeted Through Life Sciences Expertise financialpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialpost.com Daily Mail and Mail on Sunday newspapers.
Optimi Health Corp. Receives Health Canada Psychedelic Research Exemption and Files Preliminary Prospectus for Initial Public Offering of Units
January 15, 2021 09:30 ET | Source: Optimi Health Corp. Optimi Health Corp.
VANCOUVER, British Columbia, Jan. 15, 2021 (GLOBE NEWSWIRE) Optimi Health Corp. (“
Optimi” or the “
Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that it has filed a preliminary prospectus (the “
Preliminary Prospectus”) with the securities regulatory authorities in each of the provinces of Canada, except Quebec, for an initial public offering of units of the Company (the “
Units”) for gross proceeds of C$10,000,000 to C$15,000,000 (the “